Large B-cell lymphoma-<i>IRF4</i>+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm?

Huibers, Minke; Abla, Oussama; Andrés, Mara; Balagué, Olga; Beishuizen, Auke; Carraro, Elisa; Chiang, Alan; Csóka, Monika; David, Bianca-Andreea; de Ville de Goyet, Maëlle; Gilad, Gil; Hori, Daiki; Kotecha, Rishi S.; Kabickova, Edita; Klapper, Wolfram; Miakova, Natasha; Minard-Colin, Veronique; Nakazawa, Atsuko; Pillon, Marta; Rigaud, Charlotte; Salaverria, Itziar; Tölle, Ida; Verdú-Amorós, Jaime; von Mersi, Hannah; Wössmann, Wilhelm; Burkhardt, Birgit; Attarbaschi, Andishe

doi:10.1182/bloodadvances.2023012109

Blood Advances

2024

DOI: 10.1182/bloodadvances.2023012109

|View full text |Cite

Large B-cell lymphoma-IRF4+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm?

Minke Huibers,

Oussama Abla,

Mara Andrés

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Low‐grade follicular lymphoma with interferon regulatory factor‐4 rearrangement: Expanding the spectrum of interferon regulatory factor‐4‐rearranged lymphomas

Sakhdari,

Sabatini,

Geevar

et al. 2024

eJHaem

View full text Add to dashboard Cite

In recent years, the recognition of distinct lymphoma entities has expanded with advancements in molecular characterization. Large B‐cell Lymphoma with interferon regulatory factor‐4 (IRF4) rearrangement (LBCL‐IRF4‐R) is one such entity. We present a case of classic low‐grade follicular lymphoma with IRF4 rearrangement in a 50‐year‐old male, demonstrating an unusual immunophenotypic and genetic profile reminiscent of LBCL‐IRF4‐R. Molecular analysis revealed mutations in CREBBP, KMT2D, IRF4, and CARD11, with previously unreported variants identified in IRF4 and CREBBP. This case broadens the spectrum of B‐cell lymphomas associated with IRF4 rearrangement by demonstrating a small B‐cell lymphoma with this genetic feature.

show abstract

Low‐grade follicular lymphoma with interferon regulatory factor‐4 rearrangement: Expanding the spectrum of interferon regulatory factor‐4‐rearranged lymphomas

Sakhdari,

Sabatini,

Geevar

et al. 2024

eJHaem

View full text Add to dashboard Cite

show abstract

Pediatric lymphomas: overview and diagnostic challenges

Choi,

Quintanilla-Martinez

2024

Virchows Arch

View full text Add to dashboard Cite

Only 10% of new lymphoma diagnoses in the USA occur in children < 15 years. Although the same diagnostic criteria apply to both adult and pediatric lymphomas, there are important differences in some lymphoma subtypes. These differences are recognized by the World Health Organization (WHO) with the recent 2022 classification of pediatric tumors including pediatric hematopoietic tumors. Here, we review the WHO classification scheme for pediatric lymphomas and summarize the diagnostic criteria, recent genetic findings, and differences from their adult counterparts for some subtypes including those yet to be included as a definitive subtype. In general, there are differences in relatively frequency, genetic mutation, and prognosis with the pediatric counterpart often having better prognosis. Emerging B-cell lymphomas with recurrent gene alterations such as IRF4 rearrangement and 11q gain/loss chromosomal alterations will be reviewed. The overlapping pathological, clinical, and molecular features between pediatric-type follicular lymphoma (PTFL) and pediatric nodal marginal zone lymphoma (PNMZL) suggesting one disease with broad morphological spectrum will be discussed. The pathogenetic role of EBV in subclassifying Burkitt lymphoma is highlighted. The revised classification of the EBV-positive lymphoproliferative disorders in children is discussed. This review will focus on novel findings, areas of special interest, and diagnostic challenges in pediatric lymphomas.

show abstract

Bridging clinicopathologic features and genetics in follicular lymphoma: Towards enhanced diagnostic accuracy and subtype differentiation

Bosch-Schips,

Parisi,

Climent

et al. 2024

Human Pathology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Large B-cell lymphoma-IRF4+ in children and young people: time to reduce chemotherapy in a rare malignant mature B-cell neoplasm?

Cited by 6 publications

References 26 publications

Low‐grade follicular lymphoma with interferon regulatory factor‐4 rearrangement: Expanding the spectrum of interferon regulatory factor‐4‐rearranged lymphomas

Low‐grade follicular lymphoma with interferon regulatory factor‐4 rearrangement: Expanding the spectrum of interferon regulatory factor‐4‐rearranged lymphomas

Pediatric lymphomas: overview and diagnostic challenges

Bridging clinicopathologic features and genetics in follicular lymphoma: Towards enhanced diagnostic accuracy and subtype differentiation

Contact Info

Product

Resources

About